A bench comprising Chief Justice Sanjay Kishan Kaul and Justice Pushpa Satyanarayana passed the order on a petition by Panipat-based Laborate Pharmaceuticals India Limited, which has its regional office here, challenging the 4th Proviso to Sub Rule (2) of the Drugs and Cosmetic Rules notified by the Centre on July 17, 2015.
The proviso restricts sale of diclofenac injection to single unit dose of 3 ml only on the ground that the multidose vial was being misused.
The petitioner prayed the court to declare the 4th proviso as arbitrary, invalid in law and unenforceable and, in an interim plea, sought a stay on the prosecution initiated.
The company submitted that the Health Ministry in consultation with the Environment Ministry published a Gazette notification on July 17, 2015 regarding the restriction on packaging of multi-dose vial of diclofenac to single dose for human use.
The restriction was imposed on the ground that the multi-dose variant of the drug administered to cattle got ingested by vultures causing fatalities as they routinely fed on carcasses.
Counsel for the company submitted that the drug had been prohibited for animal use from July 2008 on the alleged ground of vulture deaths.
It was not made clear as to why the multi-dose package had been prohibited while the medicine was permitted for human use as an essential drug, he said.
The petitioner also said the claims about vulture deaths due to the drug did not appear to have been substantiated by any systematic, scientific, long-duration study and documented by any reliable government agency.
The matter was adjourned to February 18 next for further hearing.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
